ARUP Laboratories is prioritizing innovation in diagnostics for Alzheimer’s disease and other neurodegenerative diseases to make testing more broadly available to clinicians and patients.

Request More Info

The Alzheimer’s Association estimates that 6.7 million Americans ages 65 years and older are living with Alzheimer's disease (AD). According to the association, as the population of the United States ages, incidence of the disease will only increase, making improved diagnosis and treatment imperative.

Ensure your patients receive the best possible care and support by incorporating ARUP Laboratories’ full suite of AD testing into your diagnostic workup.

Why Choose ARUP?

people-collaboration icon

Expert Guidance

Our medical directors guide test development and are available for consultation on test ordering and result interpretation.

tests-chemistry icon

Evolving Test Menu

We continually expand our test menu based on the latest in research, guidelines, and technology.

solutions-accuracy icon

Comprehensive Testing Solutions

Our test menu includes FDA-approved cerebrospinal fluid biomarkers, phosphorylated tau 217 (pTau 217) in plasma, and apolipoprotein E (APOE) testing for amyloid-related imaging abnormalities (ARIAs) risk assessment.

people-collaboration icon

Cutting-Edge Solutions

ARUP has expertise in translating innovation to application, and we continue to seek out partners with whom we can work to develop diagnostics that will have direct clinical impact.

 

Featured Tests

Phospho-Tau 217, Plasma (3019017) Available April 21, 2025

  • Blood-based biomarkers are a less-invasive and cost-effective testing option for the diagnosis of AD. Current research supports pTau 217 as a highly accurate and specific marker for the detection of amyloid pathology.
  • Specimens from the Eli Lilly and Company I5T-MC-AACI trial (TRAILBLAZER-ALZ 2) were used to validate this assay, and it was shown to have high correlation with amyloid pathology as measured by positron emission tomography (PET) imaging.
  • The Simoa® assay kit uses pTau 217 antibody technology licensed from Eli Lilly and Company and performed on Quanterix’s SP-X® platform.

Alzheimer's Disease Markers, CSF (3017653)

  • This test uses FDA-approved kits and instrumentation. Its performance is backed by significant data, and test results have been demonstrated to closely correlate with amyloid PET scan results.
  • Test results provide two ratios: Phospho-Tau(181)/Abeta42 Ratio and Total-Tau/Abeta42 Ratio, which offer better concordance with amyloid PET imaging when compared to Abeta42, pTau 181, and tTau individually.

Apolipoprotein E (APOE) Genotyping, Alzheimer Disease Risk (2013341)

  • APOE testing is recommended if treatment with monoclonal antibodies is being considered because of the risk of ARIAs in individuals who are homozygous for the APOE e4 variant.
  • APOE testing is also useful in AD risk assessment and may be useful for genetic counseling purposes.